Clin2
NCT07137832Possibly a fitRecruiting

Testing clot-busting drug during stroke treatment for medium vessel blockages

Acute Ischemic Stroke

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
530 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have had a stroke caused by a blockage in a medium-sized brain artery (like the M2, M3, M4, A1–A3, P1–P3 segments).
  • Your stroke symptoms are at least moderately severe (NIHSS score of 6 or more).
  • Treatment can start within 6 hours of when you were last seen well, or within 6–24 hours if imaging shows brain tissue that can still be saved.
  • You do not have bleeding in the brain, a major disability before the stroke, or any serious bleeding risk.
  • You are not pregnant, do not have severe kidney problems, and are not allergic to contrast dye.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07302854Recruiting· Phase 2/Phase 3
Clot-busting medicine for medium vessel strokes

This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.

Wuhan, Hubei
NCT06559436Recruiting
Extending window for clot-busting drug in medium vessel stroke

This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.

Hefei, Anhui
NCT07469293Not yet recruiting· Phase 3
Study of artery-injected tenecteplase for stroke with medium vessel blockage

This trial tests a clot-busting drug called tenecteplase, given directly into the blocked artery, for people who have had a stroke caused by a medium-sized brain vessel blockage within the last 24 hours. It aims to see if this treatment is safe and effective in improving recovery.

Baise City, Guangxi
NCT07389460Not yet recruiting· Phase 3
Study of a clot-busting drug before thrombectomy for stroke

This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.

Lanzhou, Gansu
NCT07115940Recruiting
Clot removal after 24 hours for stroke patients

This trial tests if removing a large blood clot from the brain up to 3 days after a stroke improves recovery compared to standard medical care alone. It is for patients who have a severe stroke and are otherwise healthy enough for the procedure.

Chicago, Illinois
NCT06143488Recruiting
Clot removal vs. best medicine for mild stroke with large vessel blockage

This trial tests whether removing a blood clot from a large brain artery is better than standard medical care for people who have a mild stroke (NIHSS score 2-5) but still have symptoms like trouble speaking, weakness, or confusion. It is for patients who can be treated within 24 hours of their last known well time.

Wuhu, Anhui

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.